{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:31:33Z","timestamp":1760056293899,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jpba.2021.114105","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T13:54:22Z","timestamp":1619531662000},"page":"114105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A validated UHPLC\u2013MS\/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study"],"prefix":"10.1016","volume":"201","author":[{"given":"Jun","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingwang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114105_bib0005","first-page":"259","article-title":"The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2","volume":"61","author":"Marshall","year":"2002","journal-title":"Ann. Rheum Di"},{"key":"10.1016\/j.jpba.2021.114105_bib0010","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/14656566.8.10.1551","article-title":"Lumiracoxib in the management of osteoarthritis and acute pain","volume":"8","author":"Bannwarth","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jpba.2021.114105_bib0015","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1021\/acs.chemrestox.6b00042","article-title":"Phase I metabolic stability and electrophilic reactivity of 2-Phenylaminophenylacetic acid derived compounds","volume":"29","author":"Pang","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2021.114105_bib0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1358\/dot.2007.43.3.1062673","article-title":"Lumiracoxib","volume":"43","author":"Buvanendran","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jpba.2021.114105_bib0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1590\/S1516-31802011000500009","article-title":"Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials","volume":"129","author":"Silva","year":"2011","journal-title":"Sao Paulo Med. J."},{"key":"10.1016\/j.jpba.2021.114105_bib0030","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.3748\/wjg.v16.i45.5651","article-title":"Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?","volume":"16","author":"Bessone","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jpba.2021.114105_bib0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cld.2013.07.009","article-title":"Nonsteroidal anti-inflammatory drug-induced hepatotoxicity","volume":"17","author":"Unzueta","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jpba.2021.114105_bib0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","article-title":"Mechanisms of drug-induced liver injury: from bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpba.2021.114105_bib0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/acs.chemrestox.5b00410","article-title":"Reactive metabolites: current and emerging risk and hazard assessments","volume":"29","author":"Thompson","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2021.114105_bib0050","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/tx200168d","article-title":"Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States","volume":"24","author":"Stepan","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2021.114105_bib0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/dmd.107.019018","article-title":"In vitro metabolic activation of lumiracoxib in rat and human liver preparations","volume":"36","author":"Li","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2021.114105_bib0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/tx8002356","article-title":"Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinine imine intermediates and GSH adducts","volume":"22","author":"Kang","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2021.114105_bib0065","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/dta.2777","article-title":"Bioactivation of lumiracoxib in human liver microsomes: formation of GSH- and amino adducts through acyl glucuronide","volume":"12","author":"Jiao","year":"2020","journal-title":"Drug Test. Anal."},{"year":"2018","series-title":"Bioanalytical Method Validation","key":"10.1016\/j.jpba.2021.114105_bib0070"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:14:23Z","timestamp":1760001263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":14,"alternative-id":["S0731708521002168"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114105","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A validated UHPLC\u2013MS\/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114105"}}